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Small lipids such as eicosanoids exert diverse and complex
functions. In addition to their role in regulating normal
kidney function, these lipids also play important roles in the
pathogenesis of kidney diseases. Cyclooxygenase
(COX)-derived prostanoids play important role in maintaining
renal function, body fluid homeostasis, and blood pressure.
Renal cortical COX2-derived prostanoids, particularly (PGI2)
and PGE2 play critical roles in maintaining blood pressure
and renal function in volume contracted states. Renal medullary
COX2-derived prostanoids appear to have antihypertensive
effect in individuals challenged with a high salt diet.
5-Lipoxygenase (LO)-derived leukotrienes are involved
in inflammatory glomerular injury. LO product
12-hydroxyeicosatetraenoic acid (12-HETE) is associated with
pathogenesis of hypertension, and may mediate angiotensin
II and TGFb induced mesengial cell abnormality in diabetic
nephropathy. P450 hydroxylase-derived 20-HETE is a potent
vasoconstrictor and is involved in the pathogenesis of
hypertension. P450 epoxygenase derived
epoxyeicosatrienoic acids (EETs) have vasodilator and
natriuretic effect. Blockade of EET formation is associated
with salt-sensitive hypertension. Ceramide has also been
demonstrated to be an important signaling molecule, which
is involved in pathogenesis of acute kidney injury caused by
ischemia/reperfusion, and toxic insults. Those pathways
should provide fruitful targets for intervention in the
pharmacologic treatment of renal disease.
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An extensive body of evidence demonstrates that small lipids
participate as mediators in a variety of trans-membrane
signaling cascades, mediating multiple cellular processes such
as cell differentiation, replication, and apoptosis.1–4 These
lipids include eicosanoids, fatty acids, glycerophospholipids,
and ceramides.1–4 In addition to their roles in regulating
physiologic function, these lipid mediators have also been
demonstrated to play important roles in the pathophysiology
of inflammation, asthma, cancer, diabetes, and hyperten-
sion,1–5 pointing to potential therapeutic targets at these lipid
mediators or the enzyme responsible for their biosynthesis or
the receptor mediating their actions. The present review will
focus on the current understanding of the roles of
arachidonic acid-derived lipid mediators in mediating
normal physiologic function and pathologic events of the
kidney.
EICOSANOIDS
Eicosanoids are 20 carbon fatty acid derivatives (eicosa,
Greek for 20), produced from arachidonic acid through three
major enzymatic pathways: cyclooxygenase (COX), lipoxy-
genase (LO), and cytochrome P450 monooxygenase
(CYP450).2,3,5–7 Eicosanoids include prostanoids derived
from COX pathway, leukotrienes from LO pathway and
hydroxyeicosatetraenoic acids (HETEs) and epoxyeicosatri-
enoic acids (EETs) from P450 monooxygenase pathway.2,3,5–7
ARACHIDONIC ACID AND PHOSPHOLIPASE A2
Arachidonic acid, a precursor of eicosanoids, exists primarily
in esterified form as a glycerophospholipid in the cell
membrane. Cellular levels of free arachidonic acid available
for eicosanoid production is primarily controlled by
phospholipase A2 (PLA2).8 Thus far more than 20 PLA2s
have been identified, which have been classified into four
groups: secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2),
calcium independent PLA2 (iPLA2), and PAF acetylhydro-
lases (PAF-AH).8,9 Five members of cPLA2 family have been
identified: cPLA2a, b, d, e, z, and g.10 Among them, cPLA2a
(IVA PLA2) is best characterized and is suggested to be a key
player for arachidonic acid release.8,9 cPLA2 can be
phosphorylated by several protein kinases including mito-
gen-activated protein kinase, protein kinase C (PKC), and
Ca2þ -calmodulin-dependent kinase.11–13 Several vasoactive
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substances, such as endothelin, angiotensin II (ANG II), and
vasopressin, have been reported to activate cPLA2.14–20
These properties of cPLA2 are consistent with its critical
role in regulating arachidonic acid release and eicosanoid
biosynthesis.8,9
In the kidney, PLA2 activity can be induced by a variety of
stimuli, including oxidative stress, complement C5b-9,
hypoxia, and mechanical stretch.21–24 It has been documented
that cPLA2 can potentiate H2O2 cytotoxicity in kidney
epithelial cells and glomerular mesangial cells.25,26 cPLA2 and
its products have been reported to participate in several
pathogenic process, including diabetic nephropathy, anti-
Thy1 glomerulonephritis, and ischemic kidney injury.8,10
Recently, considerable evidence suggests that secretary PLA2s,
particularly secretory PLA2 IIa, secretory PLA2 V, and
secretory PLA2 X, are involved in atherosclerotic lesions.27–29
Their roles in the kidney remain to be defined.
COX-DERIVED PROSTANOIDS
Prostanoids are formed by conversion of free arachidonic
acid to a common intermediate, PGH2 by COX via two
enzymatic processes (Figure 1). COX first converts arachi-
donic acid to PGG2 via its bis-oxygenase activity, and the
unstable PGG2 is then converted to PGH2 by the peroxidase
activity of COX.30 PGH2 is subsequently metabolized to
more stable biologically active prostanoids including PGE2,
prostacyclin (PGI2), PGF2a, PGD2, and thromboxane A2 by
distinct synthases. Each prostanoid acts on specific and
distinct cell surface G-protein coupled receptor(s)31,32 or on
nuclear receptors such as peroxisome proliferator activated
receptor (PPAR)d and PPARg33–36(Figure 1).
Prostanoids are rapidly metabolically degraded, limiting
their effect to the immediate vicinity of their synthetic site,
accounting for their autocrine or paracrine function. The
biologic effects of COX-derived prostanoids are diverse and
complex, depending on which prostanoid is produced and
which receptor is available.31,32 Thus the effects of prosta-
noids on kidney function will rely on distinct enzymatic
machinery that couples phospholipase and COX to specific
prostanoid synthase in specific cells, yielding a specific
prostanoid, which acts, through autocrine or paracrine, on a
specific G-protein coupled receptor, exerting its distinct
effect.31
Two isoforms of COX have been identified, designated
COX1 and COX2.37–40 COX1 appears to serve a constitutive
house-keeping role, responsible for maintaining basic
physiological function such as cytoprotection of the gastric
mucosa, and control of platelet aggregation.6,30,41 Conversely,
COX2 is induced by inflammatory mediators and mitogens,
and is thought to play a key role in pathophysiologic
processes including angiogenesis, inflammation, and tumor-
igenesis.6,7,30,41 However, recent studies indicate that COX2
also serves ‘house-keeping’ functions. Gene targeting experi-
ments demonstrated a critical role of COX2 in kidney
development, in ovulation and parturition.42–45 Clinical
studies as well as animal studies also demonstrated important
role of COX2 in maintaining cardiovascular homeostasis.46–48
In the kidney, COX1 is highly expressed in the collecting
duct, and low level of COX1 can also be detected in
interstitial cells.49–51 In contrast, COX2 is predominately
expressed in renal medullary interstitial cells and in cortical
thick ascending limb and cells associated with macula densa
under normal conditions.38,49,52
PGH2, the product of COX-mediated arachidonate
metabolism, is further metabolized by prostanoid synthase.
Prostanoid synthases include PGE2 synthase (PGES),
prostacyclin synthase (PGIS), PGD synthase (PGDS),
PGF synthase (PGFS), and thromboxane synthase, respon-
sible for PGE2, PGI2, PGD2, PGF2a, and thromboxane
A2 biosynthesis, respectively.41,53 At least three PGE
synthases have been identified: microsomal PGE synthase 1
(mPGES1), microsomal PGE synthase 2 (mPGES), and
cytosolic PGE synthase (cPGES1).54–56 mPGES1 displays
a high catalytic activity relative to other PGESs.54,57 The
expression of mPGES1 is induced by cytokines and
inflammatory stimuli.54 In contrast, the expression of cPGES
and mPGES2 is not inducible.56,58 PGD2 is synthesized
from PGH2 catalyzed by PGD synthase (PGDS).59 Two
distinct types of PGDS have been identified: the lipocalin-
type PGDS (L-PGDS) and the hematopoietic PGDS (H-
PGDS).59,60 PGF2a can be synthesized from PGH2 by 9,11
endoperoxide reductase.61 PGF2a can also be synthesized
from PGE2 by PGE 9-ketoreductase.62,63 The distribution
of prostanoid synthases within the kidney is less well
characterized. In the kidney, mPGES1 is expressed in
collecting duct and medullary interstitial cells.64,65 Although
mPGES1 has been reported to be functionally coupled
to COX2,58 in renal collecting duct mPGES1 appears to be
mainly coupled to COX1.64 Low levels of mPGES2 and
cPGES are also detected in the kidney.66,67 Thromboxane
synthase is mainly detected in glomeruli.65 PGIS appears
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Figure 1 | Cyclooxygenase pathway of arachidonic acid
metabolism.
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to be mainly localized to vasculature in the kidney.65
RT-PCR showed that L-PGDS is strongly expressed in kidney
cortex and outer medulla. Whereas H-PGDS mRNA is only
detected in microdissected outer medullary collecting duct.65
PGE2 is the most abundant prostanoid in the kidney,
followed by PGI2, PGF2a, and thromboxane A2.68 Under
basal conditions, both COX1 and COX2 pathways are
responsible for the biosynthesis of these prostanoids.68 In
contrast, the COX2 pathway contributes to angiotensin II-
induced PGE2 and PGI2 generation in the kidney.68 The
cellular sites where these prostanoids are synthesized remain
to be defined.
A diverse family of membrane spanning G-protein
coupled prostanoid receptors has been cloned and character-
ized. These include the D-prostanoid (DP), EP, F-prostanoid
(FP), I-prostanoid (IP), and T-prostanoid (TP) receptors,
each of which selectively reacts with PGD2, PGE2, PGF2a,
PGI2, or TxA2, respectively.31,32 Four subtypes of EP
receptors have been cloned: EP1, EP2, EP3, and EP4.31,32
Each prostanoid receptor activates a distinct G protein-
coupled signaling pathways. The IP, DP, EP2, and EP4
receptors are coupled to the stimulatory G-protein (Gs) and
signal by increasing intracellular cyclic adenosine monophos-
phate (cAMP) level, whereas the TP, FP, and EP1 receptors
induce calcium mobilization.31,32 The EP3 receptor is
coupled to an inhibitory G-protein (Gi) and reduces cAMP
synthesis.31,32 Although some of these receptors share the
same second signaling pathway, the downstream targets of
these second signaling pathways activated by each receptor
could be different, leading to different physiological effect.
The precise signaling mechanism underlying the effect of
each prostanoid receptor has not been completely elucidated.
The intrarenal localization of these prostanoid receptors and
the consequences of their activation have been only partially
characterized.69
EP1 and EP3 mRNA expression predominates in the
collecting duct and thick limb, respectively, where their
stimulation reduces NaCl and water absorption, promoting
natriuresis, and diuresis.69 The FP receptor is highly
expressed in the distal convoluted tubule and collecting
duct, where it may exert distinct effects on renal salt
transport.70 Although only low levels of EP2 receptor mRNA
are detected in the kidney and its precise intrarenal
localization is uncertain, mice with targeted disruption of
the EP2 receptor exhibit salt-sensitive hypertension, suggest-
ing that this receptor may play an important role in salt
excretion.71,72 In contrast, EP4 receptor mRNA is predomi-
nantly expressed in the glomerulus, where it may contribute
to the regulation of glomerular hemodynamics and renin
release.31,73 The IP receptor mRNA is highly expressed in the
afferent arteriole, where it may also dilate renal arterioles and
stimulate renin release.31 Conversely, TP receptor in the
glomerulus may counteract the effects of these dilator
prostanoids and increase glomerular resistance. At present
there is little evidence for DP receptor expression in the
kidney.31
Effect of renal prostanoids on renal hemodynamics and its
role in acute renal failure
It has long been recognized that COX-derived prostanoids
play a critical role in modulating renal blood flow (RBF) and
glomerular filtration rate (GFR).74–76 Under normal condi-
tions, prostanoids seem to exert little influence on RBF and
GFR.74 However, under certain pathophysiological condi-
tions, particularly in the setting of volume contracted state
such as congestive heart failure, cirrhosis with ascites, and
nephrotic syndrome, maintenance of normal renal function
becomes dependent on prostanoids.75–78 COX inhibiting
non-steroidal anti-inflammatory drugs can cause a striking
decrease in GFR in these patients.75–78 Following the
discovery of the second isoform of COX, it was hypothesized
that the ‘house-keeping’ action of prostanoids were primarily
derived from COX1 pathway, and hoped that selective COX2
inhibitor would spare the renal hemodynamic effect of non-
selective COX inhibitor. However, clinical studies have
demonstrated that selective COX2 inhibition significantly
reduces GFR and RBF in salt-depleted volunteers or
patients.79–81 The role of COX2-derived prostanoids in
maintaining renal function has also been supported by
animal studies.51,82 The mechanism by which renal prosta-
noids modulate renal hemodynamics has not been comple-
tely defined yet. Under volume-contracted conditions,
increased levels of catecholamines, angiotensin, and vaso-
pressin act to constrict both renal and peripheral arteries.83–85
In the kidney, the effect of these vasoconstrictors is counter
balanced by vasodilators including prostanoids, preventing
RBF from falling.86,87 The receptors potentially mediating the
vasodilator effect of PGE2 and PGI2 include EP4, EP2, and IP
receptors.69,88 Recent studies show that EP4 and EP2 receptor
agonists improve renal function and/or increase survival in
nephrotoxic mercury chloride rat model of acute renal
failure,89 consistent with protective role of COX-derived
PGE2 in acute renal failure.
Renal prostanoids and blood pressure regulation
Prostanoids play an important role in modulating blood
pressure.90,91 Inhibition of endogenous prostanoid synthesis
by COX inhibiting non-steroidal anti-inflammatory drugs
may result in systemic hypertension or compromise the
control of blood pressure in subjects with pre-existing salt-
sensitive hypertension.92–94 Recent clinical studies (including
CLASS, VIGOR, TARGET, and APPROVe trials) show that
COX2 selective inhibition is also associated with hyperten-
sion.46,48,95–97 The mechanism by which COX2 inhibition
causes hypertension is not completely understood. Adminis-
tration of selective COX2 or non-selective inhibitors to
patients is frequently complicated by sodium retention and
edema,48 suggesting that COX2-derived prostanoids are
involved normally in modulating renal sodium excretion
and help maintain blood pressure.
Renal medullary COX-derived prostanoids have been
shown to play a critical role in modulating sodium
homeostasis and maintaining blood pressure98 (Figure 2).
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High-salt diet increases renal medullary COX2 expression.50
Selective inhibition of renal medullary COX2 via intrame-
dullary infusion of COX2 inhibitor causes rats on high salt
diet to develop hypertension.47,99 COX2 inhibition is
associated with reduced renal medullary blood flow,100 which
has been shown to be associated with sodium retention and
hypertension.101 The identity of the vasodilator effect of
prostanoid receptor controlling the contractile properties of
the descending vasa recta that control renal medullary blood
flow, remains uncertain, but EP2 and EP4 or IP receptors
seem likely candidates.69,83 The importance of EP2 and IP
receptors in modulating sodium homeostasis and blood
pressure is supported by studies showing that EP2 or IP
receptor deficiency is associated with salt-sensitive hyperten-
sion.71,102 Several studies also indicate that EP1 receptor or
EP3 receptor is responsible for the inhibitory effect of PGE2
on salt absorption.103,104 However, despite these convincing
in vitro effects, genetic disruption of EP1 or EP3 by gene
targeting does not cause salt retention or hypertension.69
In contrast to renal medullary COX2, renal cortical COX2
activity is associated with renin release, and increases blood
pressure (Figure 2). In settings of volume depletion, macula
densa COX2 expression is dramatically increased.49,50 This
COX2 increase following low salt diet is associated with an
increase in renin expression in the adjacent afferent
arteriole.105 COX2 inhibition or genetic knockout of COX2
markedly attenuates low-salt diet-induced renin release.105
These findings are consistent with a critical role for COX2-
derived prostaglandins in stimulating renin release and
maintaining blood pressure following extracellular volume
contraction. COX2-derived prostanoids have also been
shown to mediate renin release caused by renal artery
stenosis, contributing to high renin renovascular hyperten-
sion.106,107 Animal studies showed that aorta coarctation or
renal artery clip is associated with increased renin release and
hypertension, accompanied by increased cortical thick
ascending limb/macula densa COX2 expression.107 COX2
inhibition has been shown to reduce renin activity and
decrease blood pressure in rat with aortic coarctation.107 In
vitro or ex vivo studies demonstrate that PGE2 and PGI2 can
stimulate renin release from juxtaglomerular cells through
EP4, EP2, or IP receptors.85,108–112 Gene knockout experi-
ments show that IP receptor gene disruption attenuates the
development of hypertension in two-kidney one-clip hyper-
tensive mouse model, accompanied by reduced plasma renin
activity.106 However, deletion of EP2 or EP4 failed to reduce
blood pressure and renal renin release in the two-kidney one-
clip mice.106 Other studies show that COX2 deletion is
associated with reduced basal plasma renin concentration,
which may contribute to reduced renin release following
acute stimuli.113 More studies are required to elucidate the
precise role of prostanoids in renal afferent arteriole renin
release.
Critical role of COX2-derived prostanoids in renal
development
Reports of renal dysgenesis and oligohydramnios in offspring
of women taken non-steroidal anti-inflammatory drugs
during the third trimester of pregnancy have long implicated
prostaglandins in the promotion of renal development.50,51
This has been further confirmed by gene targeting studies in
mice. Targeted disruption of the COX2 gene but not the
COX1 gene results in renal dysgenesis, characterized by
hypoplastic glomeruli and loss of subcapsular tubules
comprising the cortical mantle.34,36,52,53 Interestingly, it
appears that COX2 activity is only required during the latter
phase of nephrogenesis, and in case of rodents, postnatal
nephrogenesis. The cellular sites at which COX2 activity is
required for nephrogenesis are unknown. Nor is the cellular
mechanism by which COX2 activity promotes nephrogenesis
known. In the developing kidney, COX2 expression is mainly
detected in developing tubule epithelial cells adjacent to
nascent glomeruli and certain population of cells in comma-
and S-shaped bodies, which appears to be the structure that
develops into macula densa53,54. Nevertheless, other studies
suggest expression of COX2 immuno-reactive protein in
mesenchyme stromal cells54 during nephrogenesis. Thus the
cellular source of COX2-derived prostanoids responsible for
kidney development remains to be elucidated.
Renal COX-derived prostanoids and diabetic nephropathy
Diabetic nephropathy is characterized by microalbuminuria,
glomerular hypertrophy, mesangial expansion with glomer-
ular basement membrane thickening, arteriolar hyalinosis,
and global glomerular sclerosis, which ultimately lead to the
progression to proteinuria and renal failure.114,115 Increased
GFR (hyperfiltration) typifies the early stages of diabetic
nephropathy.114,115 Animal studies show that in streptozotocin-
induced type I diabetic rats, renal PGE2, PGI2, and TxB2
increase.116,117 COX2 expression is also increased in the thick
ascending limb and macula densa in both type I strepto-
zotocin diabetic and type II diabetic Zucher rats.118–121
Enhanced macula densa COX2 expression has also been
reported in human diabetic kidneys.122 Selective COX2
inhibition significantly reduces glomerular hyperfiltration in
streptozotocin-induced diabetic rats, consistent with COX2-
derived prostanoids increasing RBF in the diabetic kidney.118
Renin
+
BP
–
Na
Figure 2 | Role of renal COX2 in blood pressure regulation.
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The identity of these prostanoids and their cognate receptors
involved in pathogenesis of diabetic nephropathy has not
been completely characterized. Available data have shown
that EP1 and EP3 receptor mRNA expression increases in the
kidney of streptozotocin-induced and genetic (Akita) type I
diabetic mice.123 EP1 receptor antagonist treatment amelio-
rates renal and glomerular hypertrophy, and decreases
mesangial expansion.124 TP receptor antagonist has also been
reported to attenuate proteinuria and ameliorated histologi-
cal changes of diabetic nephropathy in diabetic ApoE
(apolipoprotein E)-deficient mice.125 The role of COX-
derived prostanoids in pathogenesis of diabetic nephropathy
remains to be further explored.
LO-DERIVED EICOSANOIDS: 5-, 12-, AND 15-HETES AND
LEUKOTRIENES
Arachidonic acid can also be oxidized by LOs to form HETEs
and leukotrienes126,127(Figure 3). LOs are a family of non-
heme iron containing enzymes that insert molecular oxygen
into polyunsaturated fatty acids such as arachidonic acid and
linoleic acid.126 At least six functional human LOs have been
cloned: 5-LO (gene name: arachidonate lipoxygenase
(ALOX)5), platelet-type 12-LO (gene name: ALOX12), 12/
15-LO (leukocyte-type 12-LO for mice, 15-LO type 1 for
human, Gene name: ALOX15), epidermal-type 12-LO (gene
name: ALOXE3), 12(R)-LO (gene name: ALOX12B), and
15-LO type 2 (8-lipoxygenase in mice, Gene name:
ALOX15B).127
5-LO is the key enzyme in leukotriene biosynthesis.127 5-
lipoxygenase catalyzes the generation of leukotriene A4 in the
presence of 5-LO-activating protein. Leukotriene A4, in turn,
is converted by leukotriene A4 hydrolase to LTB4, capable of
activating LTB4 receptors. Leukotriene A4 can also be
converted to cysteinyl (cys) leukotrienes (LTC4, LTD4, and
LTE4) through leukotriene C4 synthase.126 LTC4 and LTD4
contract vascular smooth muscle cells and increase vascular
permeability.128–130 LTB4 is a potent chemotactic substance
and increases polymorphonuclear leukocyte aggregation and
adhesion to the endothelium.130 These leukotrienes are
usually released locally primarily by leukocytes. These
properties of leukotrienes are consistent with their role in
mediating inflammatory and allergic reactions.131–134 Mice
with 5-LO gene disruption exhibit a reduced inflammatory
reaction, supporting the pro-inflammatory action of 5-LO
derived metabolites.127,135
12-LO catalyzes the formation of oxidized lipids 12(S)-
HETE. Human 15-LO type 1 shares high homolog with
rodent leukocyte-type 12-LO; both can mediate the forma-
tion of 12(S)-HETE and 15(S)-HETE from arachidonic acid,
and are thus classified as 12/15-LO.126,127,136 The production
of 12(s)-HETE and 15(s)-HETE has been detected in
vascular smooth muscle cells, endothelial cells, monocytes
and platelet.137–140 Substantial evidence suggests that these
eicosanoids play important role in systemic homeostasis and
renal-cardiovascular pathology.137–140 Recent studies indicate
that 12/15-LO products are also involved in the pathogenesis
of atherosclerosis. 12/15-LO gene deletion is associated with
reduced atherosclerosis in animal models.141–144
Role of LO-derived products in glomerular injury
5-LO-derived products have been documented to play an
important role in mediating glomerular immune injury.88,145
5-LO mRNA and 5-LOX-activating protein mRNA are
detected in the glomeruli and vasa recta.146 Both leukotriene
receptor B4 and the cysteinyl leukotriene receptor type 1 are
selectively expressed in the glomerulus.146 These studies
suggest that 5-LO products are involved in regulation of
glomerular function. Glomerular synthesis of LTB4 and
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Figure 3 | Lipoxygenase pathway of arachidonic acid metabolism. (1) leukotriene A4 dydrolase; (2) Leukotriene C4 synthase.
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LTC4/LTD4 is markedly enhanced in the early course of
several forms of glomerular immune injury, including
nephroxic serum nephritis, anti-thy1 nephritis, cationic
bovine g globulin-induced glomerular injury, and passive
Heymann nephritis.145 LTD4 plays an important role in the
reduction of GFR in the acute phase of the injury by virtue of
its potent vasoconstrictor action and contraction of mesen-
gial cells.145,147 LTD4 has also been reported to increase intra-
glomerular pressure, which may be associated with portei-
nuria.148 A 5-LO-activating protein antagonist has been
shown to reduce proteinuria in patients with glomerulone-
phritis, supporting a role of leukotrienes in proteinuria.145
LTB4, a potent promoter of polymorphonuclear leukocyte
attraction, participates in glomerular damage by amplifying
polymorphonuclear leukocyte dependent mechanisms of
injury.147
Role of LO-derived metabolites in pathogenesis of diabetic
nephropathy
Accumulating evidence indicates that LO-derived products
contribute to the pathogenesis of diabetic complications
including diabetic nephropathies.136 12/15-LO is detected in
renal microvessels, glomeruli, and mesangial cells.149–151 12/
15-LO levels are increased in the glomeruli of experimental
diabetic animals.151–153 High glucose has been shown to
directly increase 12/15-LO expression in cultured mesangial
cells.152 The 12/15 LO pathway has been shown to be a
critical mediator of TGFb and ANG II-induced mesangial cell
hypertrophy and extracellular matrix accumulation.154–156
ANG II and TGFb treatment significantly increase 12-LO
mRNA expression and formation of the 12-LO product
12(S)-HETE in cultured rat mesangial cells.136 ANG II-
induced mesangial cell hypertrophy and extracellular matrix
synthesis in cultured rat mesangial cells can be blocked by an
LO inhibitor or targeted 12/15-LO gene deletion.136,154–156
Role of LOs and their metabolites in regulating blood
pressure
Clinical studies in patients with essential hypertension, show
urinary 12-HETE excretion is increased.157,158 A nonsynon-
ymous polymorphism in ALOX12, a gene encoding platelet-
type 12-LO, is associated with essential hypertension.158
Increased 12-HETE production has also been reported in
animal models of hypertension such as spontaneous
hypertensive rats and rats with renovascular hyperten-
sion.159–162 12-LO inhibitors have also been shown to
ameliorate hypertension in these animals,162,163 and 12/15-
LO gene deletion blunts the pressor response of ANG II.155
These studies are consistent with an important role of 12-LO
products in pathogenesis of hypertension. 12/15-LO defi-
ciency is associated with increased endothelial nitric oxide
synthase (eNOS) expression and activity, suggesting 12/15-
LO signaling contributes to altered NO bioactivity in vascular
disease.155 12-HETE also promotes vascular smooth muscle
cell proliferation,164–166 whereas 12/15-LO gene deletion
reduces vascular smooth muscle cell growth.167 In the kidney,
12-HETE and 15-HETE constrict renal vessels and glomer-
ular mesangial cells.88,149 When infused into the renal artery,
12-HETE decreases RBF and GFR.168 12(s)-HETE has also
been shown to contribute to the afferent arteriolar response
to angiotensin.149 In summary, there is strong evidence that
the LO system plays a key role in regulating renal function.
CYTOCHROME P-450 MONOOXYGENASES DERIVED
EICOSANOIDS: 20-HETE AND EETs
Free arachidonic acid can also be oxidized by the cytochrome
P450 monooxygenase (CYP450) to produce hydroxy- and
epoxy-arachidonic acid derivatives.5,169,170 The major
CYP450-catalyzed reactions in most tissues are mediated by
epoxygenase and o-hydroxylase activities of the CYP450
family, which are responsible for biosynthesis of EETs and 20-
HETE, respectively5,169,170 (Figure 4). Molecular biology
studies have identified members of the P450 CYP2C and
CYP4A gene subfamilies as functionally relevant epoxy-
genases and o-hydroxylases, respectively.169–172
Effects of CYP P450-derived products on renal function
CYP450 monooxygenases are expressed in renal vascular and
tubular structures and play diverse physiological and
pathophysiological functions.88,169,173 20-HETE, a P450
hydroxylase-derived product, is a potent constrictor of renal
arteries.170,174–178 The vasoconstrictor effects of 20-HETE
are mediated by blocking calcium-activated potassium
channel on vascular smooth muscle cells.170,179 Renal 20-
HETE has also been implicated in the vasoconstriction
associated with activation of tubuloglomerular feedback and
RBF autoregulation.180 20-HETE also plays an important
role in the implementation of myogenic constrictor responses
to elevation of transmural pressure in small renal arterial
vessels.175,181 In the proximal tubule and in the thick
ascending limb, 20-HETE is the primary metabolite of
arachidonic acid.88,169,173 20-HETE has been shown to
promote natriuresis by inhibiting Naþ /Kþ -ATPase activity
in proximal tubule and inhibiting the Naþ -Kþ -2Cl co-
transporter in thick ascending limb.173 EETs are produced
in the vascular endothelium by CYP2C and 2J family, and
are potent vasodilators.88,169,170,173,179 EETs are also produced
in tubules including the proximal tubule and collecting ducts
in the rodent kidney.173,182 EET has been shown to inhibit
ENaC activity,183 which may contribute their natriuretic
effect. EETs have also been shown to mediate natriuretic
effect of ANG II.169,184
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Figure 4 | CYP450 pathway of arachidonic acid metabolism.
1110 Kidney International (2007) 71, 1105–1115
r e v i e w C-M Hao and MD Breyer: Physiologic and pathophysiologic roles in lipid mediators
Role of CYP450-derived arachidonic acid metabolites in
hypertension
Substantial evidence indicates that CYP450 metabolites of
arachidonic acid play an important role in the pathogenesis
of hypertension. Renal expression of CYP4A2 and renal
production of 20-HETE are increased in spontaneous
hypertensive rats.185–187 CYP450 inhibitors attenuate the
development of hypertension in spontaneous hypertensive
rats.187,188 CYP inhibitors have also been reported to prevent
the development of hypertension in deoxycorticosterone
acetate (DOCA) salt and ANG II-induced hypertension.173
Interestingly, targeted deletion of cyp4a14 in mice is
associated with hypertension.189 Further studies shows that
cyp4a14 deletion increases renal expression of cyp4a12,
resulting in increase in renal 20-HETE synthesis, and blood
pressure,189 consistent with the pro-hypertensive effect of 20-
HETE. Cpy4a14-deficiency-induced cyp4a12 expression and
hypertension is androgen dependent.189 Clinical studies show
T8590C polymorphism of CYP4A11, a human ortholog of
murine 4a14, is also associated with hypertension.190,191 The
mechanism underlying this association of the polymorphism
of CYP4A11 and hypertension remains to be defined.
P450 epoxygenase products appear to have antihyperten-
sive effect, probably via their vasodilator effect and
natriuretic effect.88,169 In rats, high-salt diet induces epox-
ygenase activity and markedly increases the urinary levels of
its metabolites.184 Epoxygenase inhibition is associated with
salt sensitive hypertension.192 Furthermore, high-salt diet
induces renal epoxygenase in normotensive Dahl salt-
resistant rats but not in hypertensive Dahl salt-sensitive rats,
consistent with antihypertensive effect of epoxygenase
derived products following high-salt diet.192 Importantly,
deletion of mouse cyp4a10, another member of cyp4a family,
causes salt-sensitive hypertension rather than gender-depen-
dent hypertension as seen with cyp4a14 deficiency.183
Cyp4a10 gene disruption is associated with reduced urinary
EET excretion,183 and induction of cyp2c expression and
EETs synthesis with a PPARa ligand, attenuates cyp4a10
deficiency-induced salt-sensitive hypertension.183 These stu-
dies support an antihypertensive effect of cyp2c-derived EETs
following high-salt diet.
ROLE OF SPHINGOMYELIN AND CERAMIDE IN THE NORMAL
AND DISEASED KIDNEY
Ceramide is also an important signaling molecule, playing an
important role in cellular responses to stress, cell growth and
differentiation, and apoptosis.193–195 Ceramide is produced
mainly from the hydrolysis of sphingomyelin catalyzed by
sphingomyelinase193,194 (Figure 5). Ceramide can also been
generated through condensation of sphingosine or sphinga-
nine and fatty acyl-CoA by ceramide synthase195 (Figure 5).
The direct targets of ceramide include ceramide-activated
protein phosphatase, ceramide-activated protein kinase, and
protein kinase Cz. The ceramide-activated protein phospha-
tase is related to PPA2 family of phosphatase, and can be
inhibited by okadaic acid.193 A number of intracellular
signaling molecules have been demonstrated to be responsive
to cellular ceramide levels, including Raf-1, mitogen-
activated protein kinase, arachidonic acid, c-myc, the
retinoblastoma gene products, and IkB.194 Ceramide synth-
esis can be induced by 1,25(OH)2 VitD3, tumor necrosis
factor a, endotoxin, interferon g, IL-1, retinoic acid,
progesterone, and ionizing irradiation.193 Numerous stresses
that initiate apoptosis have been associated with rapid
ceramide generation, including ionizing radiation, heat
shock, oxidative stress, daunorubicin, and vincristine, con-
sistent with critical role of ceramide in apoptosis.195
It has been documented that ceramide is involved in
pathogenesis of acute kidney injury caused by ischemia/
reperfusion, toxic insults, and oxidative stress.196–199 In
normal mouse kidney cortex, C24, C22 and C16 ceramides
have been identified.200 Ischemia/reperfusion or nephrotoxic
injury (glycerol-mediated myohemoglobinuria, radiocon-
trast) causes a transient reduction of renal ceramide levels,
followed by a 2–3 fold of increase in ceramide levels.199,201,202
The increased ceramide after renal injury does not seem to be
associated with enhanced hydrolysis of sphingomyelin, as
sphingomyelinase expression is not increased but rather
reduced throughout the experiments.198 In contrast, hypoxia-
reoxygenation or radiocontrast-induced renal tubular epithe-
lial cell injury is attenuated by the ceramide synthase
inhibitor, fumonisin B1, suggesting that increased ceramide
synthase activity is responsible for increased ceramide
generation, leading to apoptotic change of the renal epithelial
cells.202,203 Of interest, recent studies in mesangial cells show
that ceramide mediates enhanced collagen synthesis in
response to homocysteine, which has been documented to
play an important role in glomerular sclerosis.204
SUMMARY
Eicosanoids exert diverse and complex functions. The specific
effect of each eicosanoid depends on sequential enzymatic
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Figure 5 | Ceramide biosynthesis.
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machinery in a specific cell, yielding a specific eicosanoid,
exerting its distinct function. The biosynthesis of each
eicosanoid is regulated at multiple levels from phospholipase
A2 that catalyzes the release of arachidonic acid to specific
enzymes that catalyze the formation of bioactive eicosanoids.
Arachidonate derived eicosanoids including prostanoids,
leukotrienes, 12/15-HETEs, EETs, and HETEs, and sphingo-
myelin-derived ceramide play important roles in maintaining
normal renal function. They are also involved in the
pathophysiology of hypertension, diabetic nephropathy, and
inflammatory or toxic glomerular injury. Those signaling
pathways should provide fruitful targets for intervention in
the pharmacologic treatment of renal disease.
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